Values First Advisors’s Biohaven Pharmaceutical Holding BHVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-6,904
Closed -$1.01M – 165
2022
Q2
$1.01M Buy
6,904
+2,587
+60% +$330K 0.71% 47
2022
Q1
$512K Buy
4,317
+315
+8% +$39.3K 0.32% 90
2021
Q4
$552K Sell
4,002
-91
-2% -$11.6K 0.33% 93
2021
Q3
$569K Sell
4,093
-2,398
-37% -$299K 0.37% 85
2021
Q2
$630K Buy
6,491
+854
+15% +$69.3K 0.43% 83
2021
Q1
$385K Buy
5,637
+768
+16% +$62.1K 0.28% 110
2020
Q4
$417K Buy
4,869
+89
+2% +$7.54K 0.33% 99
2020
Q3
$311K Sell
4,780
-1,895
-28% -$124K 0.29% 114
2020
Q2
$488K Sell
6,675
-1,430
-18% -$76.1K 0.48% 72
2020
Q1
$276K Buy
+8,105
New +$371K 0.33% 93

Other funds holding BHVN

Values First Advisors's BHVN Position: Q3 2022 in Review

Values First Advisors sold out of Biohaven Pharmaceutical Holding (BHVN) in Q3 2022, closing a stake of 6,904 shares — an estimated $1.01M sold.

Values First Advisors first reported a position in BHVN in Q1 2020 and held it in 10 quarters. The position peaked at $1.01M in Q2 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • Values First Advisors reported no remaining Biohaven Pharmaceutical Holding position as of Q3 2022 after selling out during the quarter.
  • Values First Advisors sold 6,904 Biohaven Pharmaceutical Holding shares in Q3 2022, an estimated $1.01M.
  • Values First Advisors first reported a position in Biohaven Pharmaceutical Holding in Q1 2020 and held it in 10 quarters.
  • Values First Advisors's Biohaven Pharmaceutical Holding position peaked at $1.01M in Q2 2022.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding as of Q3 2022.

Based on Values First Advisors's 13F filing for Q3 2022, filed 2 Dec 2022.